Note: Descriptions are shown in the official language in which they were submitted.
~ ~ 7~396:~
This invention relates to new compounds which are valu-
able as antibacterial agent. More particularly, it relates to
quinoline carboxylic acid derivatives, the hydrates, and the
acid addition salts thereof.
Antibacterial agents such as nalidixic acid have proved
to be highly effective in the therapy of infections caused by
gram-negative bacteria, but such agents suffer from the serious
drawback of being ineffective against numerous strains of bacte-
ria, e.g., most gram-positive bacteria and Pseudomonas aerugino-
sa. Infections caused by these bacteria have progressively in-
creased during the last two decades and are extremely refractory
to chemotherapy. The compounds of the present invention are par-
ticularly useful in that they possess potent antibacterial acti-
vity against both gram-positive and gram-negative bacteria, in-
cluding Pseudomonas aeruginosa.
The new compounds of the present invention are quino-
line carboxylic acid derivative haviny the formula:
F~3~ COOEI
the hydrates and the acid addition salts thereof, such as the
hydrochloride.
The products of the present invention are prepared by
reaching piperazine with an acid having the formula:
F ~ ~ COOH
Cl N
C2H5
., -- 1 --
i~.78961
preferably in a non-reactive solvent such as, for example, water,
alcohol, pyridine, picoline, N,N-dimethylformamide, dimethylsul-
foxide, hexamethylphosphoric triamide, or the like, or in the ab-
sence of a solvent, at a temperature between about room tempera-
ture and about 200, preferably between about 100 and 180. (The
temperature is expressed in degree C all through the specifica-
tion and claims).
The following examples serve to illustrate the inven-
tion.
EXAMPLE 1:
Preparation of l-ethyl-6-fluoro-1,4-dihydro-7-(1-pipera-
zinyl)-4-oxoquinoline-3-carboxylic acid hydrate (I).
A mixture of l-ethyl-6-fluoro-7-chloro-1,4-dihydro-4-
oxo-quinoline-3-carboxylic acid (1.9 g), piperazine hexahydrate
(15 g) and water (15 ml) was heated at 170 in a sealed tube for
1~ hours. After evaporation of the solvent, the residue was aci-
dified with diluted hydrochloric acid, heated at 100~, and the
hot solution was filtered. The filtrate was evaporated to dry-
ness. The residue was dissolved in 10% sodium hydroxide and neu-
tralized with acetic acid. The precipitate was collected, washed
with water, dried, and recrystallized from ethanol to give l-e-
thyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxoquinoline-3-car-
boxylic acid pentahydrate (I) as a colorless powder, m.p.: 226 -
227. Mass spectrum m/e: 319(M ).
EXAMPLE 2:
Preparation of 1-ethyl-6-fluoro-1,4-dihydro-7-(1-pipe-
razinyl)-4-oxoquinoline-3-carboxylic acid (II).
The compound (I) was dried at 100-200 in vacuo to give
l-ethyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxoquinoline-3-
- 30 carboxylic acid (II) as a colorless powder, m.p.: 215-220. Mass
spectrum m/e: 319(M ), 275(M -C02).
- 2-
- ~7896:1
EXAMPLE 3
-
Preparation of l-ethyl-6-fluoro-1,4-dihydro-7-(1-pipe-
razinyl)-4-oxoquinoline-3-carboxylic acid hydrochloride (III).
The compound (I) or (II) was dissolved in ethanol and
acidified with concentrated hydrochloric acid. The resulting
,
precipitate was collected, washed with ethanol, and dried to give
l-ethyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxoquinoline-3-
carboxylic acid hydrochloride (III) as colorless needles, m.p.:
abové 300.
C H N
Anal. Calcd. for C16~9O3N3ClF: 54.015.38 11.81
Found: 53.85 5.43 11.62
EXAMPLE 4-
Preparation of l-ethyl-6-fluoro-1,4-dihydro-7-(1-pipe-
razinyl)-4-oxoquinoline-3-carboxylic acid (II) and the hydrate
(I).
A mixture of l-ethyl-6-fluoro-7-chloro-1,4-dihydro-4-
oxo-quinoline-3-carboxylic acid (22 g) and piperazine hexahydrate
(160 g) was heated at 135-145 in an autoclave for 18.5 hours.
The mixture was evaporated to dryness and dissolved in 10% sodium
hydroxide. The solution was neutralized with acetic acid. The
precipitate was collected, washed with water, dissolved in 30%
acetic acid, and filtered. The filtrate was neutralized with 10%
sodium hydroxide. The resulting precipitate was collected, wash-
ed with water and ethanol, and dried at 140-145 in vacuo for
l.S hour to give 14 g (54%) of 1-ethyl-6-fluoro-1,4-dihydro-7-(1-
piperazinyl)-4-oxoquinoline-3-carboxylic acid (II) as a colorless
powder, m.p.: 227-228.
C H N
Anal. Calcd. for C16H18O3N3F: 60.18 5.68 13.16
Found: 60.31 5.70 13.24
The compound (II) was dissolved in 10% sodium hydroxide and neu-
1~7896~
lized with acetic acid. The precipitate was washed with water
and dried at room temperature to give l-ethyl-6-fluoro-1,4-dihy-
dro-7-(1-piperazinyl)-4-oxoquinoline-3-carboxylic acid hydrate
(I) as a colorless powder, m.p.: 226-227.
C H N
;Anal. Calcd. for Cl~H1803N3F.5H20: 46.94 6.89 10.26
Found: 47.34 6.68 10.30
EXAMPLE 5:
Preparation of l-ethyl-6-fluoro-1,4-dihydro-7-(1-pipe-
razinyl)-4-oxoquinoline-3-carboxylic acid (II).
A mixture of l-ethyl-6-fluoro-1,4-dihydro-7-(1-pipera-
zinyl)-4-oxoquinoline-3-carboxylic acid (0.45 g), piperazine
(0.73 g), and ~-picoline (4 ml) was heated at 140-145 for 8
hours. The reaction mixture was treated in the same way as de-
scribed in EXAMPLE 4 to give 0.34 g (64%) of 1-ethyl-6-fluoro-1,4-
dihydro-7-(1-piperazinyl)-4-oxoquinoline-3-carboxylic acid (II)
as a colorless powder, m.p.: 224-226.
It is known that most drugs such as Quinoform* and
Ethambutol* which form chelates with metal ions in vivo produce
undesirable side effects. It was reported that nalidixic acid
produces a chelate compound when treated with a ferric ion (Chem.
Abstr., 62, 15600h (1965)). When nalidixic acid was mixed with
one third molar equivalent of ferric chloride hexahydrate in the
presence of a molar equivalent of sodium hydroxide in water, the
absorption maxima at 256 and 326 nm of nalidixic acid shifted to
a shorter wave length at 248 and 311 nm, respectively, and a 3 : 1
chelate compound of nalidixic acid and ferric ion was obtained.
On the other hand, the compound (II) of the present in-
vention did not give any chelate compound when treated with a fer-
ric ion under the above condition.
The usefulness of the compounds of the present inventionas antibacterial agent has been demonstrated by the following ex-
* Trademark
4 -
:J ~78961
periments.
Experiment 1. Antibacterial activity (in vitro).
The minimum inhibitory concentration (M.I.C.) of the
compound (II) was assayed by the agar dilution streak method a-
gainst four strains of Pseudomonas aeruginosa and other pathogenic
-~- bacteria. As shown in Table 1, nalidixic acid and pipemidic acid
exerted antibacterial activity mainly on gram-negative bacteria
and were inactive on many strains of gram-positive bacteria and
many Pseudomonas aeruginosa strains, which are gram-negative. On
the other hand, the compound (II) was more active than nalidixic
acid and pipemidic acid against both gram-positive and gram-
negative bacteria, and it was proved to be more active than genta-
micin and carbenicillin against gram-negative bacteria including
Pseudomonas aeruginosa.
Compound (II) showed a broad spectrum of activity a-
gainst gram-positive and gram-negative bacteria, and it was a-
chieved even against those bacteria which were not susceptible to
treatments with nalidixic acid, pipemidic acid and carbenicillin.
Thus, cornpound (II) is a promising antibacterial agent
which is more potent and has broader antibacterial activity a-
gainst pathogenic bacteria including Pseudomonas aeruginosa than
other synthetic chemotherapeutic agents.
- 5 -
g61
Table 1 Antibacterial spectrum
M. I. C. (,ug/ml)
Organisms Gram
Compound PPA ~A GM CBPC
(II)
Bacillus subtilis PCI 219 + 0.396.25 6.25 0.10 0.39
Staphylococcus aureus
209P + 0.7825 1000.10 0.39
Sta. aureus ATCC 14775 +1.56 100>100 0.10 6.25
Streptococcus pyogenes
IID 692 + 3.13~100~1006.250.10
Str. pyogenes S-8 + 1.56~lO0>1006.250.10
Str. faecalis IID 682 +3.13 - - 50 100
Diplococcus pneumoniae
IID 552 + 12.5,~100>10012.50.39
Corynebacterium pyogenes
IID 548 + 3.13100 -0.78 0.20
Mycobacterium phlei
IFO 3142 + 0.3912.51006.25 >200
20 My. smegmatis IFO 3083 +1.56 50~100 0.20 6.25
Escherichia coli NIHJ -0.10 1.563.13 0.39 1.56
E. coli ATCC 10536 - 0.051.563.130.391.56
Proteus vulgaris IFO 3167 - 0.053.13 3.13 0.20 6.25
Pr. vulgaris XK Denken -0.20 6.253.13 0.10 0.39
Klebsiella pneumoniae
IFO 3512 - 0.051.561.560.20~200
Salmonella enteritidis
IID 604 - 0.2012.512.51.5612.5
Shigella sonnei IID 969 -0.10 1.561.56 0.78 1.56
Haemophilus influenzae
IID 986 - 0.053.131.561.560.39
Neisseria perflava IID 856 -0.051.56 1.56 0.78 1.56
Pseudomonas aeruginosa V-l -0.39 12.5 100 0.78 12.5
Ps. aeruginosa IFO 12689 -1.56 25 ~200 12.5 100
Ps. aeruginosa IID 1210 - 1.56 50 7200 12.5 100
Ps. aeruginosa IID 1130 - 0.7825 72003.13 200
,~ ,
1178~6~
PPA: Pipemidic acid, NA: Nalidixic acid, GM: Gentamicin
CBPC: Carbenicillin.
Experiment 2. Preventive effect of compound (II) against system-
ic infection produced by Pseudomonas aeruginosa in mice.
Systemic infection was produced by intraperitoneally
inoculating male mice (strain: ddY, 6 weeks old, body weight: 28
to 33 g) with Pseudomonas aeruginosa IID 1210 suspended in 0.5 ml
of Brain heart infusion broth (Eiken) containing 5% mucin. The
compound (II) and pipemidic acid were suspended in 0.5% carboxy-
methyl cellulose solution, respectively, and carbenicillin wasdissolved in water. Each of these test materials was administered
twice to the mice, immediately after and then 6 hours after the
inoculation, and the therapeutic effect of each compounds was
judged from the survival rate. A comparison of the compound effi-
ciency was made with a 50% effective dose (ED50) calculated by
probit analysis (1) and a 95% confidence limit that was calcula-
ted by the method of Litchfield and Wilcoxon (2). As shown in
Table 2, the compound of Example 2 effectively protected the mice
from Pseudomonas aeruginosa infection, and it was confirmed that
it was more potent than pipemidic acid and carbenicillin. The
LDlo of the compound (II) is over 4g/kg in mice and therefore
compound (II) is excellent in a safety zone LDlo/ED90 over 21.6.
(1) Miller L.C. and M.L. Tainter: Estimation of the ED50
and its error by means of logarithmic-probit graph paper Proc.
Soc. Exp. Biol. Med. 57 261-264 (1944).
(2) Litchfield J.T. and F. Wilcoxon: A simplified method
of evaluating dose - effect. J. Pharmacol. 92 99 - 113 (1948).
~ - 7 -
~896~
Table 2 Preventive effect of compound (II) against systemic
infection with Pseudomonas aeruginosa in mice
Compounds Challenge dose ED50 (mg/kg) EDgo
(cells/mouse) (95% confidence limit) (mg/kg)
,
Compound (II) 3.5 x 104 98.0 (79.7 - 120.5) 185
Pipemidic acid 3.5 x 104 400 (317 - 504) 1120
Carbenicillin 3.5 x 104 800 (630 - 1,016) 1430
Compound (II) and Pipemidic acid were administered orally,
Carbenicillin was administered subcutaneously.
Experiment 3. Preventive effect of compound (II) against rising
kidney infection in mice caused by Escherichia coli.
Rising kidney infection was induced in female mice
(strain: ddY, 6 weeks old, body weight: 22 to 26 g), by instilling
Escherichia coli NI~IJ JC-2 suspended in 0.04 ml of Tryptosoya
broth (Nissan) into the urinary tract of mice anesthetized with
sodium pentobarbital and by holding the mice for 6 hours in plas-
tic tubes (diameter 25 mrn) and clamping the outlet of the urinary
tract. The compound (II), nalidixic acid and pipemidic acid were
suspended in a 0.5% carboxy methyl cellulose solution, respective-
ly. Each of these test material was orally administered 3 hoursafter inoculation. The rnice were sacrificed 48 hours after ino-
culation. The kidneys were removed aseptically and bisected, and
the two halves were pressed and streaked on agar p]ate containing
a desoxycholate medium (Nissan). The therapeutic effect of each
compound was evaluated by the absence of growth on the agar sur-
face after 20 hours of incubation at 37". A comparison of the
compound efficiency was made with a 50% effective dose (ED50) cal-
culated by probit analysis and a 95% confidence limit tha-t was
calculated by the method of Litchfield and Wilcoxon.
As shown in Table 3, the compound of Example 2 was effec-
~ ~
-~78961
tive against ascending kidney infection in mice caused by Esche-
richia coli and it was confirmed that compound (II) was more po-
tent than nalidixic acid and pipemidic acid.
The LD1o of compound (II) is over 4 g/kg in mice and
compound (II) is excellent in safety zone LDlo/EDgo over 65.6.
Table 3 Preventive effect of compound (II) against rising kidney
infection in mice caused by Escherichia coli
Compounds Challenge dose ED50 (mg/kg) EDgo
(cells/mouse) (95% confidence limit) (mg/kg)
Compound (II) 3.2 x 10 15.0 (8.6 - 26.3) 61
Nalidixic acid 3.2 x 107 86.0 (45.3 - 163) 345
Pipemidic acid 3.2 x 107 74.0 (51.0 - 107) 235
Experiment 4. Concentrations of the compound (II) in serum after
a single oral administration of 50 mg/kg in rats.
The concentrations of the compound (II) in serum were
determined by microbiological assays. Nutrient agar was heated
and melted. Escherichia coli NIHJ JC-2 was added to melted agar,
thoroughly mixed, and 5 ml of the mixture was placed in a Petri
dish. Penicylinders were placed on the solidified agar, and each
cylinder was filled with a serum sample. The plate was placed in
an incubator at 37 for 20 hours. The diameter of the inhibition
zone was measured. The serum was sampled at 0.5, 1, 2, 4, 6 hours
after adrninistering the compound (II) in rat.
The serum concentrations of compound (II) after a single
oral administration of 50 mg/kg are shown in Table 4. The abso~
tion of the compound (II) was rapid, and the concentration peak
took place 30 min. after oral administration. The antibacterial
activity of the compound (II) was not decreased by the serum.
_ g _
1~7896~ .
Table 4 Serum concentration of compound (II) after a single
oral administration of 50 mg/kg in rat
-
Time after administration Concentration ~lg/ml
,, ,
0.5 0.87 + 0.11
0.77 - 0.13
2 0.52 + 0.10
4 0.23 + 0.02
6 0.11 + 0.01
Experiment 5. Concentrations of compound (II) in serum 30 min.
10 after a single oral administration in rats.
The concentrations of compound (II) in serum in rats
30 minutes after a single oral administration are shown in Table
5. The concentrations of compound (II) in serum were assayed by
the microbiological method described in experiment 4. The anti-
bacterial activity of the compound (II) did not decreased by se-
rum. The serum concentration of the compound, depending on the
dose, varied from 25 mg/kg to 400 mg/kg.
Table 5 Concentration of compound (II) in serum 30 min. after
a single oral administration in rats
Dose (mg/kg) Concentration (~ug/ml) mean - S.E.
0.31 + 0.04
0.87 + 0.11
100 1.42 + 0.23
200 2.23 + 0.30
400 3.37 + 0.35
Experiment 6. Concentration ratio of compound (II) in serum, to
minimum inhibitory concentration (M.I.C.), on pathogenic bacteria
after oral administration of 50 mg/kg in rats.
- 10 -
7~
- In the drawings which illustrate the invention,
Figure l shows curves representing the concentration
ratios of compound (II), nalidixic acid and pipemidic acid,
in serum of rats, to M.I.C. on Escherichia coli ATCC 10536,
Figure 2 shows curves representing the concentra-
tion ratios of compound (II), nalidixic acid and pipemidic
acid, in serum of rats, to M.I.C. on Pseudomonas aeruginosa
V-l: and
Figure 3 shows curves representing the concentra-
tion ratios of compound (II), nalidixic acid and pipemidicacid, in serum of rats, to M.I.C. on Staphylococcus aureus
20gP.
- lOa -
~J
7896~L
As shown in Figs. 1 to 3, the absorption of the com-
pound (II) was rapid, and the serum concentration was 18 times
that of M.I.C. on Escherichia coli, 30 minutes after oral adminis-
tration and 2 times, 6 hours after oral administration. On the
otherhand, the concentration ratios of nalidixic acid and pipe-
midic acid were smaller than that of the compound tII) and the
serum levels of pipemidic acid were maintained only until 2 hours
after oral administration.
The compound (II) could be expected to be more effec-
tive than nalidixic acid and pipemidic acid against infections
of the above bacteria. In addition, compound (II) could be ex-
pected to be more effective than those of nalidixic acid and pi-
pemidic acid against infections caused by Pseudomonas aeruginosa
and gram-positive bacteria.
Experiment 7. Concentrations of compound (II) in tissues after
a single oral administration of 50 mg/kg in rats.
Concentrations of compound (II) in tissues were assayed
by the microbiological method described in experiment 4 except
that a tissue homogenate was used instead of serum.
The tissue homogenates were prepared with 1 : 4 homo-
genates in M/15 phosphate buffer (pH 7.5). Free concentration
was calculated from a standard curve of the compound (II) in
M/15 phosphate buffer. The total concentration was calculated
from a standard curve of the compound (II) in a tissue homogenate.
The tissue concentrations of compound (II) after a
single oral administration of 50 mg/kg were shown in Table 6 and
7.
The antibacterial activity of the compound (II) was de-
creased by liver and kidney homogenate.
' .;;~
-- 11 --
11~8g61
Table 6 Concentration of compound (II) in tissues after a
single oral administration of 50 mg/kg in rats
(Free concentration) Tissue level (,ug/g)
0.5 1 2 4 6 (hrs)
Liver 4.1 + 0.9 3.7 + 0.6 2.5 + 0.5 1.2 + 0.2 0.7 + 0.1
Kidney 7.4 - 1.4 6.8 - 1.2 4.4 - 0.6 1.9 + 0.2 1.0 - 0.1
mean - S.E.
Table 7
(Total concentration) Tissue level (,ug/g)
0.5 1 2 4 6 (hrs)
Liver 9.0 - 1.9 7.9 + 1.2 5.4 + 1.0 2.6 + 0.4 1.5 + 0.2
Kidney 11.1 + 2.1 10.3 + 2.0 6.5 + 0.9 3.5 + 1.0 1.4 + 0.1
mean + S.E.
Experiment 8. Tissue levels of 14C-labeled compound (II) in rats
after oral administration.
The distribution of compound (II) was studied in rats
which were orally given a single dose of 50 mg 14C-compound (II)/
kg. The tissue levels of compound (II), 30 minutes after adminis-
tration are shown in Table 8.
0 I'able 8 Tissue levels of 14C-compound (II) in rats after oral
administration (50 mg 14C-compound/kg )
Tissue 30 min. after administration
Blood 1.41 + 0.44 ygEq/ml
Lung 1.91 - 0.48 ygEq/g
Liver 11.09 - 4.78
Kidney 11.42 - 2.40 "
Bladder 15.10 - 20.28 "
Bone 0.73 - 0.28 "
- 12 -
1~78961
Experiment 9. siliary excretion in rats after a single oral
administration of 50 mg/kg of compound (II).
The concentrations of compound (II) in bile of rats
after a single oral administration of 50 mg/kg are shown in Table
9, and the cumulative recovery is shown in Table 10.
The concentrations of compound (II), nalidixic acid and
. pipemidic acid in the bile were assayed by the microbiological
method described in experiment 4.
The biliary levels and cumulative excretion of compound
(II) were much better than those of nalidixic acid and pipemidic
acid. The antibacterial activity of compound (II), nalidixic
acid and pipemidic acid was not influenced by the bile of rats.
Table 9 Concentrations of compound (II) in bile after a single
oral administration of 50 mg/kg in rats
... .. . _ _ _ _
Time after Biliary level (,ug/ml) mean - S.E.
administration ~~
Nalldixic Pipemidic
(~ours) Compound (II) acid acid
. . _ _ . _ . . _
0 - 3 31.0 + 3.5 14.7 + 1.5 27.4 + 2.6
3 - 6 26.4 + 3.2 16.6 + 2.4 22.6 + 1.7
20 6 - 24 18.9 + 1.6 9.3 + 1.6 10.2 + 1.2
24 - 27 6.7 - 0.9 -* _*
-* Not detected ( ~2 ,ug/ml)
Table 10 Biliary excretion in rats after a single oral adminis-
tration of 50 mg/kg of compound (II)
Time after Cumulative recovery (%) mean - S.E.
administration Nalidixic Pipemidic
(hours) Compound (II) acid acid
0 - 3 0.60 + 0.06 0.29 + 0.030.60 + 0.07
0 - ~ 1.02 + 0.11 0.56 + 0.051.01 + 0.10
30 0 - 24 2.43 - 0.23 1.33 + 0.101.97 + 0.09
0 - 27 2.50 + 0.23 1.33 + 0.101.97 + 0.09
- ~78961
Experiment 10. Concentrations of compound (II) in urine of rats
and mice after a single oral administration.
As shown in Table 11, the concentrations of compound
(II) in urine were assayed by the microbiological method de-
scribed in experiment 4. The compound is rdpidly transferred to
~` urine and the concentrations peak were observed at 0 to 6 hours.
Table 11 Concentrations of compound (II) in urine of rats and
mice after a single oral administration
Dose Time after
Urinary level (,ug/ml) mean - S.E.
(mg/kg) administration
(hours) Rat Mouse
,
1.56 0 - 3 1.36 -+ 0.14 0.53 ~ 0.06
3 - 6 0.93 + 0.14 0.22 -+ 0.04
6 - 24 0.17 + 0.05 0.04 - 0.03
24 - 27 0.04 - 0.01 0.03 - 0.02
3.13 0 - 3 3.39 -+ 0.55 1.76 -+ 0.19
3 - 6 3.78 + 0.44 1.46 -+ 0.23
6 - 24 0.58 -+ 0.09 0.27 + 0.04
24 - 27 0.03 + 0 0.14 + 0.01
6.25 0 - 3 9.69 + 2.30 3.70 +- 0.26
3 - 6 8.08 -+ 1.50 2.04 + 0.13
6 - 24 1.3~ -+ 0.20 3.01 t 0.17
24 - 27 0.04 -+ 0 0.38 + 0.05
12.5 0 - 3 21.29 -+ 3.6 10.3 + 0.9
3 - 6 16.8 -+ 1.6 8.3 + 0.7
6 - 24 4.0 + 0.5 7.4 -+ 0.8
- 24 - 27 0.06 - 0.02 1.2 - 0.1
A .~
~:~78961
Table 11 (cont'd)
Dose Time after Urinary level (~g/ml) mean + S.E.
(mg/kg) administration
(hours) Rat Mouse
_
25.0 0 - 356.8 + 11.116.2 + 3.3
3 - 646.4 + 3.820.3 + 1.7
6 - 2413.5 + 3.011.7 + 0.9
24 - 271.2 + 0.5 2.5 + 0.2
- 50.0 0 - 389.3 + 19.533.1 + 2.8
3 - 699.2 + 15.927.2 + 3.2
6 - 2432.2 + 0.123.1 + 2.0
24 - 273.1 + 0.9 7.7 + 1.1
Experiment 11. Acute toxicity.
The acute toxicity of compound (II) was examined in
mice (ddY strain, 7 weeks old) and rats (Wistar strain, body
weight 180 - 230 g). The observation period was 10 days, either
after a single oral, subcutaneous or intravenous administration.
The LD50 value was determined by the Litchfield-Wilcoxon method.
The results are shown in Table 12.
Table 12 LD50 values of compound (II)
- Animal Route of Sex LD50 my/kg
administration (95% confidence limit)
-
Mice oral male :, 4,000
female ~ 4,000
subcutaneous male ~1,500
- female ~1,500
intravenous male 210 (194 - 227)
female 221 (207 - 236)
117896~
Table 12 (cont'd)
Animal Route of Sex LD50 mg/kg
administration (95% confidence limit)
Rats oral male ~4,000
female >4,000
subcutaneous male >1,500
female >1,500
intravenous male 305 (288 - 323)
Experiment 12. Subacute toxicity study.
The subacute toxicity study of compound (II) was car-
ried out in rats by orally administering 250, 500 and 1000 mg/kg
during 1 month.
The results show that no effects of the test compound
were observed in general symptoms, namely food and water consump-
tions, body weight, hematological analysis, hemato-biochemical
analysis, differential counts of myelocytes, biochemical analysis
of liver and kidney, urinary analysis, organ weight, gross obser-
vation and histopathological findings.
Experiment 13. Effects on chromosome.
The effects of compound (II) on the chromosomes of myel-
ocytes were tested by orally administering 250 and 500 mg/kg,
once in Chinese hamster, and lO00 mg/kg in rats for l month. No
effects of the test compound on the chromosomes of myelocytes
were observed in both species.
Experiment 14. Teratogenicity study.
The teratological study of compound (II) was carried out
in mice by orally administering 500 and lO00 mg/kg during the
period of organogenesis.
The results indicated that compound (II), showed no
sign of being a teratogenic agent.
- 16 -
